Short answer: Patients on GLP-1 receptor agonist therapy eat considerably less, often eat a narrower range of foods, and digest more slowly — and the published literature suggests that combination can leave measurable gaps in vitamin D, vitamin B12, iron, magnesium, calcium, zinc and folate, alongside a loss of lean mass that reviews have put at roughly a quarter to two-fifths of total weight lost when protein intake and resistance training are not actively protected. The usual clinic response is a retail multivitamin, which fixes the ratios for the manufacturer’s convenience rather than the patient’s blood results and adds several capsules a day to someone whose appetite and tolerance are already compromised. A compounding pharmacy changes three things: the doses can follow the patient’s actual labs, the number of units can collapse into a single preparation, and the delivery form can move from a capsule to a liquid or a liposomal preparation when nausea and slowed gastric emptying make swallowing capsules unappealing. Every Lynnity preparation — supplements included — is made only against a prescription from a registered doctor, under the Ministry of Health’s Good Compounding Practice (GCP) guideline. There is no direct-purchase route.
GLP-1 and dual GLP-1/GIP therapies have moved from specialist endocrinology into general weight-management practice across Kuala Lumpur, the Klang Valley and Singapore faster than the supporting nutritional protocols have. Clinics running these programmes are now dealing with a second-order problem the prescribing guidance says relatively little about: what to do about intake when intake falls by a third or more and stays there for a year. This guide is written for those prescribers and their dietetic colleagues.
Why nutrient gaps appear — three separate mechanisms
It is worth separating the mechanisms, because they call for different responses.
1. Total intake falls, and stays down
Appetite suppression is the therapeutic effect, not a side effect. But a sustained reduction in energy intake is also a sustained reduction in everything that arrived with that energy. A patient eating substantially less for twelve months is, by arithmetic, taking in less iron, less calcium, less folate and less of everything else — and micronutrient requirements do not fall in proportion to appetite.
2. The diet narrows, not just shrinks
Clinically this is the more interesting one. Patients frequently report altered taste and new food aversions, and red meat, oily foods and dense protein sources are among the most commonly abandoned. That is a targeted loss rather than a proportional one: it strips out precisely the foods that carry haem iron, zinc and B12. Two patients with the same calorie reduction can end up with very different deficiency profiles depending on which foods they stopped eating.
3. Digestion and absorption change
GLP-1 agonists slow gastric emptying and small-intestinal motility — a well-documented pharmacological effect that has been studied for its influence on the absorption of co-administered medicines, where it has been shown to delay the time to peak concentration and alter overall exposure. For nutrients, the practical consequences are the ones patients notice: early satiety, nausea, and a reduced appetite for the fat-containing meal that fat-soluble vitamins need in order to be absorbed properly.
The lean-mass problem
This is the issue metabolic clinics increasingly raise first. Weight loss on GLP-1 therapy is predominantly fat mass, but it is not exclusively fat mass. Reviews of body-composition data suggest that without structured nutritional support, a substantial minority of the weight lost — figures in the region of a quarter to two-fifths are commonly cited — is lean tissue. Comparative work using routine-care body-composition data has also reported differences between agents, with tirzepatide associated with greater relative lean-mass decline than semaglutide over twelve months. These are observational and modelling-based findings rather than settled fact, and they should be read as a reason to monitor rather than as a fixed expectation for any individual patient.
The mainstream response in the nutrition literature is protein intake in the region of 1.2–1.6 g per kilogram of body weight per day, paired with resistance training. That is a dietetic intervention, and it belongs with the dietitian — a compounding pharmacy does not replace it. What a pharmacy can contribute sits alongside it: the micronutrient cofactors that muscle protein synthesis and bone maintenance depend on, prepared at doses that reflect the patient’s measured status rather than a generic label.
What clinicians are monitoring
| Nutrient | Why it comes up on GLP-1 therapy | Compounding relevance |
|---|---|---|
| Vitamin D | The most frequently reported abnormality in review data on this population; fat-soluble, so absorption is tied to a fat-containing meal that may no longer be eaten. | Dose set to the measured 25(OH)D level; can be given as a liquid taken with the largest meal. |
| Vitamin B12 | Serum levels have been reported to drift downward over 3–6 months in some patients, and the foods carrying B12 are among the first to be dropped. | Methylcobalamin, at a prescriber-set strength; a sublingual liquid held under the tongue bypasses the gastric step entirely. |
| Iron & ferritin | Reduced red-meat intake removes the most bioavailable dietary source. | Form and elemental dose specified by the doctor; a liquid is often better tolerated where nausea is already present. |
| Magnesium | Flagged in professional advisories on this population; also relevant to the constipation many patients report. | Salt form and strength are the whole argument — see our magnesium compounding guide. |
| Calcium & vitamin K2 | Bone health during rapid weight loss; dairy is a common aversion. | Prepared to the prescriber’s ratio rather than a fixed commercial one. |
| Zinc | Named alongside calcium and magnesium in obesity-medicine advisories on GLP-1 nutrition. | Narrow therapeutic window against copper — a case where dose precision genuinely matters. |
| Folate | Reduced overall intake; relevant in any patient of reproductive age. | Active folate forms where the prescriber requests them. |
Baseline testing before therapy starts, with repeat testing at intervals the prescriber decides, is what turns this table from a shopping list into a protocol. Lynnity does not order or interpret laboratory tests — that is the doctor’s role — but a formulation built on a result is a materially different object from one built on a marketing claim.
Why the off-the-shelf multivitamin fits badly here
A retail multivitamin is a compromise designed for a population, and this population sits some distance from the average. Four problems recur.
The ratios are fixed. A patient with a low ferritin and a normal vitamin D gets the same relative doses as a patient with the opposite pattern. One of them is receiving something they do not need in order to receive something they do.
The unit count goes the wrong way. Covering the list above from retail products commonly means four to seven separate items a day. Asking someone with drug-induced early satiety and intermittent nausea to swallow that is an adherence problem disguised as a nutrition plan.
The form is fixed too. Every retail line is built around what the manufacturer can produce at scale. If a patient cannot tolerate capsules during a titration week, there is no route to the same nutrients in another form.
The excipient list is not the prescriber’s. Fillers, colourings and capsule-shell materials are chosen for manufacturing convenience, which matters for patients with intolerances or dietary requirements — and this cohort tends to be highly attentive to what they are putting in.
What a compounded approach changes
Doses that follow the labs
The prescriber specifies each component and each strength. Where a result sits at the low end, that component can be raised; where it is adequate, it can be reduced or left out. Over a twelve-month programme with repeat testing, the formulation can be revised rather than replaced with a different brand.
Consolidation into one preparation
Where clinically appropriate and chemically compatible, several prescribed components can be prepared as a single capsule instead of a handful of separate products. Reducing unit count is one of the few adherence levers that works reliably in a patient whose tolerance for swallowing anything is reduced. Our pharmacists confirm compatibility and stability before anything is combined — not every combination is achievable, and we say so when it is not.
A form the patient can actually take
This is where the therapy’s own pharmacology argues for compounding. When nausea and delayed gastric emptying make capsules unattractive, the prescriber can specify:
- an oral liquid, dosed by volume, which is easier to take in small amounts through a difficult titration week;
- a sublingual liquid held under the tongue, which is particularly relevant for B12 because it does not depend on the stomach at all;
- a tonic taken with the day’s largest meal, for the fat-soluble components;
- a measured powder dispersed into a liquid, where a patient prefers that.
Lynnity compounds capsules, liquids, creams, tonics and serums. We do not make softgels or tablets, and where a commercial softgel or tablet is the only retail option for a nutrient, a compounded liquid or capsule is the route we can offer instead.
Liposomal preparations where absorption is the constraint
For the fat-soluble and poorly absorbed components, our core capability is directly relevant. A liposomal preparation carries the nutrient inside a phospholipid bilayer resembling the body’s own membranes. We build ours using ultrasonic technology: high-frequency sound creates and collapses microscopic cavities in the lipid dispersion, and those micro-implosions shear the lipid into small, uniform vesicles. Vesicle size and uniformity are a direct function of the energy applied — an energy density mechanical mixing does not reach. The intent is a consistent, reproducible vesicle population. We describe what the process does; we do not attach an absorption percentage or a clinical outcome to it. More on how liposomal delivery works.
What Lynnity does and does not do here
To be unambiguous: Lynnity does not compound, supply or dispense GLP-1 or GLP-1/GIP receptor agonists in any form. The patient’s weight-management therapy is prescribed and supplied entirely separately by their doctor. Our involvement begins and ends with the nutritional support formulations that doctor decides to prescribe alongside it.
We are also not a manufacturer. Lynnity is a compounding pharmacy preparing individual, prescription-led formulations for named patients under GCP, with defined beyond-use dating and record-keeping. GCP is the compounding-specific quality framework and is not the same as GMP, which governs large-scale manufacturing. We do not contract-manufacture, wholesale or produce own-label ranges.
The practitioner workflow
The route is the same as for any Lynnity formulation. The doctor assesses the patient — ideally with baseline bloods before GLP-1 therapy begins — and decides which nutrients to prescribe, at what strengths, in which delivery form and on what review interval. That prescription comes to us; our pharmacists confirm the formulation is achievable, compatible and appropriate to compound; and the preparation is made under GCP and dispensed for the named patient. Clinics in KL, the Klang Valley and Singapore that do not compound in-house are welcome to discuss the workflow with our pharmacy team before the first prescription is written, so that achievable strengths, combinations, delivery forms and beyond-use dating are clear in advance. There is no route by which a patient or a clinic obtains one of these preparations from us without that prescription.
Frequently asked questions
Does Lynnity compound semaglutide, tirzepatide or other GLP-1 medications?
No. Lynnity does not compound, supply or dispense GLP-1 or GLP-1/GIP receptor agonists in any form. We prepare only the nutritional support formulations that a registered doctor prescribes alongside a patient’s separately prescribed therapy.
Can a patient on a GLP-1 medication buy compounded supplements from Lynnity directly?
No. Every Lynnity preparation, supplements included, requires a prescription from a registered doctor. There is no direct-purchase, walk-in or online-order route, and no product of ours can be obtained without that prescription.
Which nutrients are most often monitored in patients on GLP-1 therapy?
Published reviews and professional advisories most often name vitamin D, vitamin B12, iron and ferritin, magnesium, calcium, zinc and folate, together with protein intake and lean-mass status. Which of these apply to an individual patient is a clinical judgement based on their history, diet and laboratory results — the prescriber’s decision, not the pharmacy’s.
Why not just use a retail multivitamin?
A retail multivitamin has fixed ratios chosen for a general population, a fixed delivery form and a fixed excipient list, and covering a full nutrient list usually means several separate products a day. A compounded preparation lets the doctor set each dose against the patient’s own results, consolidate where compatible, and choose a form the patient can tolerate.
What if the patient is too nauseated to swallow capsules?
The prescriber can specify an oral liquid, a sublingual liquid held under the tongue, a tonic taken with the largest meal, or a measured powder dispersed into a liquid. Lynnity compounds capsules, liquids, creams, tonics and serums; we do not make softgels or tablets.
Do supplement formulations interfere with GLP-1 therapy?
Standard vitamins and minerals are not generally described as interacting with these medicines, but GLP-1 agonists do slow gastric emptying, which can alter the timing and extent of absorption of things taken by mouth. Timing instructions — for example, taking fat-soluble components with the largest meal — are part of the prescription and are set by the prescribing doctor, who is also the person to review the patient’s full medication list.
How do clinics in KL or Singapore start working with Lynnity on this?
Speak to our pharmacy team before writing the first prescription. We will go through achievable strengths, which combinations can be prepared together, available delivery forms and beyond-use dating, so the prescription you write is one we can prepare exactly as specified.
Reviewed by the Lynnity pharmacy team, Kuala Lumpur.
This article is general professional information for practitioners and is not medical advice, a treatment recommendation, or a claim that any formulation diagnoses, treats, cures or prevents any disease. Lynnity preparations are compounded only against a prescription from a registered doctor and are not registered products. Lynnity does not compound or supply GLP-1 receptor agonists.